Anti-PD1 checkpoint inhibitor with or without chemotherapy for patients with recurrent and metastatic nasopharyngeal carcinoma

•We assessed 67 patients with R/M NPC treated with anti-PD1 checkpoint inhibitor+ chemotherapy (n = 26) or anti-PD1 checkpoint inhibitor alone (n = 41).•The incidence of HPD was higher in the anti-PD1 checkpoint inhibitor group compared with anti-PD1 checkpoint inhibitor+ chemotherapy group (39.0% v...

Full description

Saved in:
Bibliographic Details
Published in:Translational oncology 2021-02, Vol.14 (2), p.100989-100989, Article 100989
Main Authors: Jin, Ting, Zhang, Qun, Jin, Qi-Feng, Hua, Yong-Hong, Chen, Xiao-Zhong
Format: Article
Language:English
Subjects:
Anti-PD1 checkpoint inhibitor
Chemotherapy
Metastasis
Nasopharyngeal carcinoma
Original Research
Recurrence
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•We assessed 67 patients with R/M NPC treated with anti-PD1 checkpoint inhibitor+ chemotherapy (n = 26) or anti-PD1 checkpoint inhibitor alone (n = 41).•The incidence of HPD was higher in the anti-PD1 checkpoint inhibitor group compared with anti-PD1 checkpoint inhibitor+ chemotherapy group (39.0% vs 3.8%, p
ISSN:1936-5233
1936-5233
DOI:10.1016/j.tranon.2020.100989